Part 1 - Introduction by Dr. M B Agarwal, Mumbai
Part 2 - Levonadifloxacin:The true multi-spectrum MRSA drug for immunocompromised host - Dr. Jaishid
Part 3 - Role of Rituximab in CLL - Dr. Dipanjan Haldar, Mumbai
Part 4 - CLL guidelines in 2020 (NCCN) - Dr. Rajiv Kumar, Bengaluru
Part 5 - CLL guidelines in 2020 (ESMO) - Dr. Gaurav Prakash, Chandigarh
Part 6 - Approved targeted therapies in CLL - Dr. Tuphan Kanti Dolai, Kolkata
Part 7 - CLL management with COVID - Dr Sadashivudu Gundeti, Hyderabad
Part 8 - Vote of Thanks - Mr. Anil Rajani, Janssen Oncology